Jan 7, 2025 · 1. In a cohort of adults with chronic obstructive pulmonary disease (COPD), receiving fluticasone-umeclidinium-vilanterol was not associated with improved clinical outcomes compared to receiving budesonide-glycopyrrolate-formoterol. Evidence Rating Level: 2 (Good) Treatment recommendations for chronic obstructive pulmonary disease (COPD) include triple inhaler combination therapy with an ...

Nov 21, 2024 · 1. In this randomized controlled trial, adjuvant therapy with durvalumab led to improved overall and progression-free survival compared to placebo in patients with limited-stage small cell lung cancer (SCLC). 2. Durvalumab had a tolerable safety profile, with a comparable incidence of adverse effects to the placebo group. Evidence Rating Level: 1 (Excellent) Study Rundown: Small

Dec 2, 2024 · 2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting.

Oct 9, 2024 · 1. In this randomized controlled trial of men aged 50 to 60, forgoing prostate biopsies in those with elevated PSA but negative MRI reduced the diagnosis of clinically insignificant cancer. 2. MRI-negative men who did not undergo prostate biopsy did not have higher rates of incurable cancer diagnoses in follow-up screenings. Evidence Rating Level: 1

Nov 18, 2024 · 1. The 2-year progression-free survival was 50.6% in the durvalumab group vs 63.7% in the cetuximab group with HR 1.33 (non-significant). 2. Regarding safety, grade 3-4 adverse events occurred in 61% for durvalumab and 79% for cetuximab. Evidence Rating Level: 1 (Excellent) Study Rundown: Concurrent radiotherapy with cisplatin is the standard treatment for locoregionally advanced

Oct 3, 2024 · 1. In this randomized controlled trial, among patients with moderately to severely active ulcerative colitis, tulisokibart, a monoclonal antibody directed against TL1A, more effectively induced clinical remission compared with placebo. 2. Compared with placebo, the tulisokibart group consistently showed benefits in clinical response, endoscopic improvement, histologic improvement, symptomatic ...

Dec 10, 2024 · 1. In this randomized controlled trial, in older adults with non-ST-segment elevation myocardial infarction (NSTEMI), invasive treatment did not significantly reduce the composite risk of cardiovascular death or nonfatal MI compared to conservative treatment. 2. There were fewer occurrences of fatal or nonfatal MI in patients in the invasive-strategy group than in the conservative-strategy group.

Dec 12, 2024 · 1. In this randomized controlled trial, two cycles of neoadjuvant ipilimumab plus nivolumab resulted in longer event-free survival than adjuvant therapy with nivolumab in patients with resectable, macroscopic stage III melanoma. 2. In this trial, neoadjuvant therapy had higher rates of adverse effects and toxicity than adjuvant therapy.

Dec 4, 2024 · 1. BMD may differ on paretic and nonparetic sides in stroke patients with a history of falling and balance deficits Evidence Rating Level: 2 (Good) There is an increased risk of fracture due to poststroke osteoporosis. These injuries particularly affect the hip. However, current recommendations rarely recommend bone mineral density (BMD) measurements as a follow-up